Application of a translational research platform to unveil efficacy signals and mechanisms of resistance of FGFR inhibitors in multiple FGFR-altered solid tumors.

Authors

Cinta Hierro, Mònica Sánchez-Guixé, Gabi Tarcic, Sarit Schwartz, Todd Hembrough, Tyler Moss, Kenna R Shaw, Funda Meric-Bernstam, Cristina Saura, Mafalda Oliveira, Rodrigo Dienstmann, Jose Jiménez, Paolo Nuciforo, Ana Vivancos, Elena Garralda, Josep Tabernero, Violeta Serra, Jordi Rodon

Published in

Clinical cancer research : an official journal of the American Association for Cancer Research. Jul 13, 2026. Epub Jul 13, 2026.

Abstract

The predictive value of FGFR amplifications (amp) and the role of FGFR mutations (mut) beyond known activating variants remain unclear. We aimed to establish a translational research platform to characterize FGFR alterations (alt) and explore their potential as predictive biomarkers for FGFR-targeted agents.
This ambispective study included a retrospective analysis of patients with FGFR-alt tumors treated with selective FGFR inhibitors (FGFRi) and a prospective collection of longitudinal tumor samples. Patient-derived xenografts (PDX) were generated to investigate FGFRi mechanisms of action and resistance. Molecular characterization included genomic, transcriptomic, proteomic and functional analyses using the Functional Annotation for Cancer Treatment (FACT™) assay.
Among 36 retrospectively analyzed patients, clinical benefit from FGFRi was observed in cases with FGFR mRNA over-expression or FGFR2/11q co-amp, but no association was found with the amplification levels. In archival tumor samples, exploratory proteomic analysis showed FGFR1-4 protein expression in 78% of FGFR1/2-amp tumors detected by FISH. RNA sequencing identified a higher prevalence of FGFR mRNA over-expression than proteomic analysis. Among patients harboring FGFR-mut, only one bladder cancer with a FGFR3-mut S249C derived benefit. FACT™ assay supported the functional activity of selected variants, including FGFR3 T689M, and suggested potential resistance mechanisms involving PI3K/PTEN and MAPK pathway co-alterations. A prospective FGFR-alt PDX biorepository enabled exploratory biomarker analyses, supporting the hypothesis that FGFR1-4 mRNA expression may better reflect FGFR dependency than genomic alterations alone.
These findings highlight the complexity of FGFR-driven oncogenesis and support integrative molecular approaches to refine patient selection for FGFR-targeted therapies.

PMID:
42440358
Bibliographic data and abstract were imported from PubMed on 13 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.